This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) | MicrobiomeTrials
← Back to trials NCT07463183
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-03-24Est. Completion: 2027-10-28
Enrollment target: 100 participantsLocations Clinnova Research ( Site 1042), Anaheim, California, United States Southern California Research Center ( Site 1044), Coronado, California, United States Peak Gastroenterology Associates ( Site 1052), Colorado Springs, Colorado, United States South Denver Gastroenterology, PC ( Site 1068), Englewood, Colorado, United States Nature Coast Clinical Research ( Site 1045), Inverness, Florida, United States Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072), Miami, Florida, United States Gastroenterology Associates of Central Georgia ( Site 1060), Macon, Georgia, United States University of Kansas Medical Center ( Site 1077), Kansas City, Kansas, United States Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 1073), New Orleans, Louisiana, United States BVL Research - Kansas ( Site 1054), Liberty, Missouri, United States Prairie Institute of Liver and Luminal Advanced Research ( Site 1008), Lethbridge, Alberta, Canada Centre Hospitalier de l Universite de Montreal - CHUM ( Site 1001), Montreal, Quebec, Canada Servicios de Salud IPS Suramericana S.A.S. - IPS Sura Industriales Medellín ( Site 1163), Medellín, Antioquia, Colombia Other microbiome trials you might be interested in Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …
Bethesda, United States Est. completion Jun 1, 2036
Inflammatory Bowel Disease (IBD)
This observational study will use intestinal ultrasound images to help develop computer programs that may make it easier…
Vancouver, Canada Est. completion Feb 1, 2027
Clinica de la Costa S.A.S. ( Site 1161), Barranquilla, Atlántico, Colombia
Fundacion Santa Fe de Bogota ( Site 1165), Bogota, Cundinamarca, Colombia
Fundación Valle del Lili ( Site 1162), Cali, Valle del Cauca Department, Colombia
Centre Hospitalier Dr Schaffner ( Site 1288), Lens, Pas-de-Calais, France
Clinique Jules Verne ( Site 1284), Nantes, Pays de la Loire Region, France
Evangelismos General Hospital of Athens ( Site 1362), Athens, Attica, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 1361), Athens, Attica, Greece
Radboudumc ( Site 1650), Nijmegen, Gelderland, Netherlands
Amsterdam UMC, locatie VUmc ( Site 1651), Amsterdam, North Holland, Netherlands
PROMED P. LACH R. GLOWACKI SP. J. ( Site 1447), Krakow, Lesser Poland Voivodeship, Poland
Melita Medical Sp Zoo ( Site 1442), Wroclaw, Lower Silesian Voivodeship, Poland
EB Group Sp. Z o.o. Centrum Zdrowia MDM ( Site 1449), Warsaw, Masovian Voivodeship, Poland
Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś ( Site 1448), Warsaw, Masovian Voivodeship, Poland
Twoja Przychodnia - Szczeciskie Centrum Medyczne ( Site 1450), Szczecin, West Pomeranian Voivodeship, Poland
Wonju Severance Christian Hospital ( Site 1602), Wŏnju, Kang-won-do, South Korea
Korea University Ansan Hospital ( Site 1603), Ansan-si, Kyonggi-do, South Korea
Kangbuk Samsung Hospital ( Site 1601), Seoul, South Korea
Fairfield General Hospital ( Site 1524), Bury, Lancashire, United Kingdom
Huddersfield Royal Infirmary ( Site 1522), Huddersfield, York, United Kingdom Phase 3
Completed
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or…
Dothan, United States Completed Jun 24, 2025